Compare Gilead Sciences, Inc. (GILD) vs Genworth Financial Inc Common Stock (GNW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Genworth Financial Inc Common Stock — how do they compare? Gilead Sciences, Inc. trades at $154.53 (market cap $183.41B), while Genworth Financial Inc Common Stock trades at $8.82 (market cap $3.36B). The key difference: Gilead Sciences, Inc. is far larger — about 54.6× Genworth Financial Inc Common Stock's market cap, and Gilead Sciences, Inc. pays a 2.22% dividend while Genworth Financial Inc Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 112 Days and Genworth Financial Inc Common Stock for 0 Days on average.
| GILD | GNW | |
|---|---|---|
Market Cap | $183.41B | $3.36B |
Volume | 5,557,651 | 3,333,156 |
Sector | Health | Financials |
52-Week High | $155.80 | $10.60 |
52-Week Low | $117.85 | $7.94 |
Typical Hold Time | 112 Days | 0 Days |
Enterprise Value | $206.48B | $2.87B |
Dividend Yield | 2.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $153.54, up 2.07% today, near its consensus price target of $153.13. The stock shows a bullish technical trend with strong moving average signals. Recent earnings beat expectations in Q2 2026, though the company posted a net loss. Revenue growth is steady, with 2025 revenue at $29.44B, but profitability metrics like ROE and net income margin are negative. Positive news includes expanded HIV drug access in Latin America.
The outlook is mixed: analyst consensus is bullish with 65.52% buy ratings, but high debt and negative margins pose risks. Key catalysts include oncology pipeline advances and HIV franchise growth, while execution risks and competitive pressures remain concerns for investors.
Genworth Financial (GNW) trades at $8.89, down 1.77% today, with neutral technical signals and mixed fundamental performance. The company maintains stable revenue around $7.1-7.2B but faces margin pressure, with net income declining from $223M to $212M year-over-year. Recent Q2 2026 earnings beat expectations at $0.29 EPS, while the company expanded its share repurchase program by $500M in September 2026.
GNW presents value characteristics with low P/B (0.38) and P/S (0.49) ratios, but weak profitability metrics (ROE 2.42%) and analyst caution (70.59% hold rating) suggest limited near-term catalysts. Key risks include legacy insurance liabilities and competitive pressures, while the upcoming Q3 earnings on November 4 could provide directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Genworth Financial Inc Common Stock
Genworth Financial, Inc. is a holding company that provides products and services related to aging and long-term care planning, and is the parent company of publicly traded mortgage insurer Enact Holdings, Inc.
Read more on GNW →
